Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial -

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Information type: Randomised controlled trials
Source: The Lancet Oncology
Specialities: Cancers | Haematological disorders
Summary
RCT (n=559) reports addition of pomalidomide to bortezomib and dexamethasone significantly improved progression-free survival at median follow-up 15.9 months (median 11.2 vs 7.1 months respectively, HR 0.61, p<0.0001).
UKMi comment

A related editorial discusses the implications of the results of this study, highlighting that pomalidomide, bortezomib, and dexamethasone possibly represents one of the future standards of care in lenalidomide-refractory patients, particularly at first relapse.
Related links: Comment